An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

Part of paid clinical trials in Chestnut Hill, Massachusetts.

Sponsor
Blueprint Medicines Corporation
Study ID
NCT07264959
Status
Recruiting
Apply to this trial

Conditions

  • Indolent Systemic Mastocytosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is a Phase 4, non-interventional, observational study to collect detailed data on the clinical characteristics, clinical outcomes and medical management of ISM in real-world settings. The study will describe the demographic and clinical characteristics of ISM participants, including anaphylaxis and bone manifestations in ISM. Quality of life and disease control will be assessed through participant questionnaires. The study will also evaluate real world ISM treatment management, including use of avapritinib.

Key Dates

Start date
Apr 15, 2026
Status verified
Apr 2026
Primary completion
Dec 1, 2032
Completion
Dec 1, 2032

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Participants With ISM
    Patients who are currently being treated or plan to be treated for ISM

Primary Outcome Measure

Baseline Demographics [ Time Frame: Baseline (Month 1) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's Allergy and Clinical Immunology, Mass General Brigham Healthcare Center (Chestnut Hill)Chestnut HillMassachusetts02467-

Find similar trials in Chestnut Hill, MA

By research site
Brigham and Women's Allergy and Clinical Immunology, Mass General Brigham Healthcare Center (Chestnut Hill)· Chestnut Hill, MA

Related Studies